Blog

The esophagus is a specialized muscular tube responsible for transporting ingested food boluses, liquids, and saliva from the pharynx to the stomach via coordinated primary and secondary peristaltic waves. Under normal physiological conditions, the esophageal mucosa is lined by non-keratinized stratified squamous epithelium that acts as a robust barrier against chemical, mechanical, and microbial injury. Unlike other segments of the gastrointestinal tract—such as the stomach, small intestine, and colon—the normal esophageal mucosa is completely devoid of resident intraepithelial eosinophils. Normal deglutition (swallowing) relies on the mechanical compliance and elasticity of the esophageal wall, allowing the lumen to distend smoothly as a food bolus passes toward the lower esophageal sphincter. Eosinophilic Esophagitis (EoE) is a chronic, immune-mediated inflammatory disorder of the esophagus characterized clinically by symptoms of esophageal dysfunction and histologically by dense, eosinophil-predominant inflammation. This chronic immune response disrupts normal tissue architecture, driving tissue remodeling, luminal narrowing, and severe dysphagia.

Immunological Etiology and TH2-Mediated Inflammatory Pathways

The underlying pathophysiology of Eosinophilic Esophagitis involves a complex interaction between genetic susceptibility, environmental triggers, and antigen-driven allergic responses. The disease is primarily driven by a T-helper type 2 (TH2) immune response triggered by food allergens—most commonly dairy products, wheat, eggs, soy, nuts, and seafood—and, to a lesser extent, ingested aeroallergens. Antigen-presenting cells within the esophageal mucosa internalize these food proteins and present them to naive T helper cells, inducing their differentiation into TH2 cells. Activated TH2 cells secrete key pro-inflammatory cytokines, specifically Interleukin-4 (IL-4), Interleukin-5 (IL-5), and Interleukin-13 (IL-13). IL-5 plays a pivotal role in promoting the maturation, survival, and trafficking of eosinophils from the bone marrow into systemic circulation. Simultaneously, IL-13 and IL-4 stimulate esophageal epithelial cells to secrete eotaxin-3 (CCL26), a potent chemokine that selectively recruits circulating eosinophils across the mucosal barrier directly into the esophageal squamous epithelium.

Mechanisms of Mucosal Infiltration and Tissue Remodeling

Once recruited into the esophageal mucosa, eosinophils become activated and degranulate, releasing cytotoxic granule proteins into the surrounding tissue. These cytotoxic proteins include major basic protein (MBP), eosinophil cationic protein (ECP), eosinophil peroxidase (EPO), and eosinophil-derived neurotoxin (EDN). The release of major basic protein and eosinophil cationic protein directly damages epithelial cell membranes, causing apical cell detachment, basal zone hyperplasia, dilated intercellular spaces (spongiosis), and epithelial barrier breakdown. As mucosal disruption worsens, TGF-beta (Transforming Growth Factor-beta) and matrix metalloproteinases (MMPs) are released by activated eosinophils and mast cells. TGF-beta acts as the central driver of tissue remodeling: it stimulates subepithelial fibroblasts to proliferate and differentiate into myofibroblasts, accelerating the synthesis and extracellular deposition of type I and type III collagen within the lamina propria and submucosa. Over time, this chronic subepithelial fibrosis causes thickening of the basal membrane and loss of normal tissue elasticity.

Pathophysiology of Dysphagia and Food Impaction

The structural remodeling and chronic inflammation seen in Eosinophilic Esophagitis directly impair deglutition mechanics through two primary mechanisms: physical mechanical obstruction and altered neuromuscular motility. Subepithelial collagen deposition and chronic muscularis propria hypertrophy reduce the caliber and distensability of the esophageal lumen. Visually, this transmural inflammation produces classic endoscopic features, including concentric mucosal rings (trachealization), longitudinal furrows, white mucosal exudates (eosinophilic microabscesses), and diffuse luminal narrowing or stricture formation. When an individual swallows a solid food bolus, the rigid, non-compliant esophageal wall fails to expand, causing the bolus to stall against the narrowed lumen. This generates the cardinal clinical symptom of EoE: solid-food dysphagia (the sensation of food sticking or passing slowly through the chest). If a food bolus becomes completely wedged within a fibrostenotic stricture or hyper-ringed segment, acute Foreign Body/Food Impaction occurs—a medical emergency requiring urgent therapeutic upper endoscopy to retrieve or dislodge the impacted food. Additionally, eosinophilic inflammation impairs local enteric neural networks, causing esophageal dysmotility, uncoordinated peristaltic contractions, and non-cardiac chest pain.

Age-Dependent Clinical Manifestations and Behavioral Adaptations

Eosinophilic Esophagitis affects individuals across all age demographics, exhibiting a notable male predominance (roughly three-to-one ratio) and a strong association with other atopic disorders, including asthma, allergic rhinitis, and atopic dermatitis. However, the clinical presentation varies significantly based on age. In infants and toddlers who cannot articulate symptoms of dysphagia, EoE presents with non-specific gastrointestinal distress: feeding refusal, vomiting, regurgitation, failure to thrive, and irritability. School-aged children frequently present with recurrent abdominal pain, heartburn refractory to acid-suppressive therapy, vomiting, and slow eating habits. Adolescents and adults predominantly exhibit classic solid-food dysphagia, acute food impactions, and chest pain. Adults with long-standing, undiagnosed EoE often adopt subtle compensatory eating behaviors to prevent dysphagia, such as chewing food excessively, cutting food into miniature pieces, taking small bites, drinking large quantities of liquids with every mouthful, and avoiding dense, dry foods like meat and bread.

Diagnostic Protocols, Endoscopy, and Histological Verification

Establishing a definitive diagnosis of Eosinophilic Esophagitis requires a structured approach combining clinical evaluation, Esophagogastroduodenoscopy (EGD), and histopathological examination of esophageal mucosal biopsies. Diagnostic guidelines require performing multiple mucosal biopsies from both the proximal/mid and distal esophagus during endoscopy. Histological confirmation requires demonstrating an peak eosinophil count of at least 15 eosinophils per high-power field (HPF) within the esophageal squamous epithelium. Microscopic examination also reveals secondary features of allergic inflammation, such as eosinophilic microabscesses, surface desquamation, and basal zone hyperplasia extending beyond fifteen percent of total epithelial thickness. Importantly, secondary causes of esophageal eosinophilia—such as Gastroesophageal Reflux Disease (GERD), achalasia, Crohn's disease, infection, and hypereosinophilic syndrome—must be thoroughly evaluated and excluded.

Therapeutic Management and Disease-Modifying Strategies

The primary goals of treating Eosinophilic Esophagitis are to eliminate mucosal inflammation, achieve histological remission (reducing intraepithelial eosinophils to under 15/HPF), relieve dysphagia, and reverse or prevent fibrostenotic esophageal remodeling. Management utilizes three main therapeutic pillars: dietary interventions, pharmacotherapy, and endoscopic procedures. Dietary elimination therapies—such as the Six-Food Elimination Diet (SFED) or targeted allergy-guided diets—identify and remove triggerfood antigens, leading to histological remission in a significant portion of patients. Pharmacotherapy relies on Topical Swallowed Corticosteroids (such as fluticasone propionate or oral viscous budesonide), which are swallowed to coat the esophageal mucosa directly, suppressing local TH2 cytokine production and eosinophil recruitment. Proton Pump Inhibitors (PPIs) are also effective, acting through both anti-secretory mechanisms and independent anti-inflammatory effects that block eotaxin-3 expression. Biologic therapies targeting the IL-4/IL-13 signaling pathway (such as dupilumab) offer targeted systemic treatment for refractory or severe cases. For patients with established, symptomatic fibrostenotic strictures or severe luminal ring narrowing, Endoscopic Esophageal Dilation using balloon or bougie dilators mechanically expands the lumen, providing immediate relief from severe dysphagia.

Conclusion

Eosinophilic Esophagitis is a chronic TH2-mediated allergic inflammatory disorder characterized by dense mucosal eosinophilic infiltration and progressive subepithelial fibrosis. Understanding how IL-5 and eotaxin-3 recruit activated eosinophils to release cytotoxic proteins clarifies the structural transition from mucosal inflammation to concentric ring formation, strictures, and loss of esophageal compliance. Utilizing upper endoscopy with multi-site mucosal biopsy quantification enables clinical teams to establish an accurate diagnosis and differentiate EoE from acid-reflux disorders. Through targeted dietary elimination, topical swallowed corticosteroids, biologics, and timely endoscopic esophageal dilation, healthcare professionals can effectively suppress allergic inflammation, restore normal deglutition mechanics, and optimize long-term health outcomes for affected individuals.